Please use this identifier to cite or link to this item:
Title: Effect of amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function
Authors: Vutisiri Veerasarn
Pramook Phromratanapongse
Nan Suntornpong
Vicharn Lorvidhaya
Vimol Sukthomya
Imjai Chitapanarux
Chanawat Tesavibul
Thiti Swangsilpa
Cholakiet Khorprasert
Kanjana Shotelersuk
Yongyut Kongthanarat
Apichart Panichevaluk
Sunanta Chiewvit
Pawana Pusuwan
Monreudee Aekmahachai
Samart Ratchadara
Sasitorn Sirilipoche
Yuttana Saengsuda
Keywords: Medicine
Issue Date: 1-Dec-2006
Abstract: Background: Amifostine has a potential role for salivary gland protection in head and neck cancer patients who had radiotherapy. Material and Method: Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine. The efficacy of the treatment was determined by a questionnaire evaluating dryness of mouth and the oral comfort, the RTOG/EORTC acute/late radiation morbidity scoring criteria, collection of the whole saliva and the 99mTc-pertecnetate scintigraphy of the salivary glands. Results: Amifostine significantly reduced the mean questionnaire scores from 6.49 to 3.73, the incidence of grade ≥ 2 mucositis from 75% to 36% and acute xerostomia from 82% to 39%. The salivary gland function returned to normal at a rate of 36.3% in the Amifostine group versus 9.1% in the control group. Conclusion: Amifostine is effective in reducing the incidence and severity of acute mucositis, acute and late xerostomia in head and neck cancer patients.
ISSN: 01252208
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.